[CAS NO. 348086-71-5] Pritelivir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [348086-71-5]

Catalog

HY-15303

Brand

MCE

CAS

348086-71-5

DESCRIPTION [348086-71-5]

Overview

MDL	-
Molecular Weight	402.49
Molecular Formula	C18H18N4O3S2
SMILES	O=C(N(C1=NC(C)=C(S(=O)(N)=O)S1)C)CC2=CC=C(C3=NC=CC=C3)C=C2

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex , exhibits antiviral activity in vitro and in animal models of herpes simplex virus ( HSV ) infection . Pritelivir is active against herpes simplex virus types 1 and 2 ( HSV-1 and HSV-2 ) with the IC ₅₀ of 0.02 μM against HSV1-2 ^[1] .

IC50 & Target

HSV-1

0.02 μM (IC ₅₀ )

HSV-2

0.02 μM (IC ₅₀ )

In Vivo

Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex ^[2] .
Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis ^[3] .
Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice ^[3]
Dosage:	0.03 to 45 mg/kg
Administration:	Administered orally, twice daily at approximately 12 h intervals, for 7 days
Result:	Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02871492	AiCuris Anti-infective Cures AG\|Novella Clinical	Herpes Labialis	November 29, 2016	Phase 2
NCT01047540	AiCuris Anti-infective Cures AG\|FHI 360	HSV-2	March 2010	Phase 2
NCT01658826	AiCuris Anti-infective Cures AG\|Medpace, Inc.	Genital Herpes	October 2012	Phase 2
NCT05513625	AiCuris Anti-infective Cures AG	HSV Infection	July 13, 2020	Phase 1
NCT03073967	AiCuris Anti-infective Cures AG\|Medpace, Inc.	HSV Infection	May 8, 2017	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 33 mg/mL ( 81.99 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4845 mL	12.4227 mL	24.8453 mL
5 mM	0.4969 mL	2.4845 mL	4.9691 mL
10 mM	0.2485 mL	1.2423 mL	2.4845 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-

N-[5-(Aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)benzeneacetamide

BAY 57-1293

N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide

Pritelivir